EA201200631A1 - Ингибиторы репликации вируса иммунодефицита человека - Google Patents

Ингибиторы репликации вируса иммунодефицита человека

Info

Publication number
EA201200631A1
EA201200631A1 EA201200631A EA201200631A EA201200631A1 EA 201200631 A1 EA201200631 A1 EA 201200631A1 EA 201200631 A EA201200631 A EA 201200631A EA 201200631 A EA201200631 A EA 201200631A EA 201200631 A1 EA201200631 A1 EA 201200631A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitors
immunodeficiency virus
human immunodeficiency
virus replication
replication
Prior art date
Application number
EA201200631A
Other languages
English (en)
Inventor
Йюла С. Тсантризос
Марри Д. Бейли
Франсуа Билодо
Ребека Дж. Карсон
Рене Куломб
Ли Фейдер
Тедди Халмос
Стивен Кавай
Серж Ландри
Стивен Лапланте
Себастьен Морен
Матьё Паризьен
Марк-Андре Пупар
Брюно Симоно
Original Assignee
Джилид Сайенсиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40638275&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201200631(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Джилид Сайенсиз, Инк. filed Critical Джилид Сайенсиз, Инк.
Publication of EA201200631A1 publication Critical patent/EA201200631A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems

Abstract

В заявке описаны соединения формулы Iв которой значения R, Rи Rопределены в настоящем изобретении, применимые в качестве ингибиторов репликации ВИЧ.
EA201200631A 2007-11-16 2008-09-11 Ингибиторы репликации вируса иммунодефицита человека EA201200631A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98868607P 2007-11-16 2007-11-16

Publications (1)

Publication Number Publication Date
EA201200631A1 true EA201200631A1 (ru) 2012-11-30

Family

ID=40638275

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201200631A EA201200631A1 (ru) 2007-11-16 2008-09-11 Ингибиторы репликации вируса иммунодефицита человека
EA201000777A EA019259B1 (ru) 2007-11-16 2008-09-11 Ингибиторы репликации вируса иммунодефицита человека

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201000777A EA019259B1 (ru) 2007-11-16 2008-09-11 Ингибиторы репликации вируса иммунодефицита человека

Country Status (26)

Country Link
US (3) US8354429B2 (ru)
EP (2) EP2757096A1 (ru)
JP (2) JP5285709B2 (ru)
KR (1) KR20100097156A (ru)
CN (1) CN101918365B (ru)
AR (1) AR069335A1 (ru)
AU (1) AU2008323558C1 (ru)
BR (1) BRPI0820307A2 (ru)
CA (1) CA2707418C (ru)
CL (1) CL2008003406A1 (ru)
CO (1) CO6280400A2 (ru)
EA (2) EA201200631A1 (ru)
EC (1) ECSP10010206A (ru)
HK (2) HK1147096A1 (ru)
IL (1) IL205581A (ru)
MA (1) MA31906B1 (ru)
MX (1) MX2010005334A (ru)
NZ (1) NZ585226A (ru)
PE (3) PE20091000A1 (ru)
SG (1) SG185995A1 (ru)
TN (1) TN2010000212A1 (ru)
TW (1) TWI437992B (ru)
UA (1) UA100250C2 (ru)
UY (1) UY31472A1 (ru)
WO (1) WO2009062285A1 (ru)
ZA (1) ZA201003283B (ru)

Families Citing this family (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2220076B1 (en) * 2007-11-15 2012-01-18 Boehringer Ingelheim International GmbH Inhibitors of human immunodeficiency virus replication
UA100250C2 (ru) * 2007-11-16 2012-12-10 Гілеад Сайнсіз, Інк. Ингибиторы репликации вируса иммунодефицита человека
CA2745295C (en) 2008-12-09 2017-01-10 Gilead Sciences, Inc. Modulators of toll-like receptors
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
JP5984218B2 (ja) * 2010-07-02 2016-09-06 ギリアード サイエンシーズ， インコーポレイテッド Ａｉｄｓを処置するためのナフト−２−イル酢酸誘導体
BR112012033689A2 (pt) * 2010-07-02 2019-09-24 Gilead Sciences Inc derivados de ácido 2-quinolinil-acético como compostos de hiv antivirais
US8633200B2 (en) 2010-09-08 2014-01-21 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
KR20140003438A (ko) 2010-11-15 2014-01-09 카톨리에케 유니버시테이트 루벤 항바이러스성 축합 헤테로사이클릭 화합물
JP2014511859A (ja) * 2011-04-04 2014-05-19 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖインテグラーゼ阻害剤の調製のためのプロセス
EP2694160A1 (en) * 2011-04-04 2014-02-12 Gilead Sciences, Inc. Solid state forms of hiv inhibitor
EP2508511A1 (en) 2011-04-07 2012-10-10 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2511273B8 (en) * 2011-04-15 2019-06-26 Hivih Inhibitors of viral replication, their process of preparation and their therapeutical uses
ES2707997T3 (es) 2011-04-21 2019-04-08 Gilead Sciences Inc Compuestos de benzotiazol y su uso farmacéutico
EP2729448B1 (en) 2011-07-06 2015-09-09 Gilead Sciences, Inc. Compounds for the treatment of hiv
ES2624984T3 (es) 2011-07-15 2017-07-18 Viiv Healthcare Uk Limited Derivados de ácido 2-(pirrolo[2,3-b]piridin-5-il)-2-(t-butoxi)-acético como inhibidores de la replicación del VIH para el tratamiento del SIDA
US8791108B2 (en) 2011-08-18 2014-07-29 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
ES2632443T3 (es) * 2011-09-22 2017-09-13 Viiv Healthcare Uk Limited Compuestos de pirrolopiridinona y procedimientos de tratamiento del VIH
EP2772480B2 (en) 2011-10-25 2020-12-09 Shionogi & Co., Ltd. Hiv replication inhibitor
PT2781519T (pt) * 2011-11-15 2019-12-17 St Pharm Co Ltd Novo derivado de pirrolopiridina antiviral e um método de produção do mesmo
WO2013103738A1 (en) * 2012-01-04 2013-07-11 Gilead Sciences, Inc. Napthalene acetic acid derivatives against hiv infection
WO2013103724A1 (en) * 2012-01-04 2013-07-11 Gilead Sciences, Inc. 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids
US8629276B2 (en) 2012-02-15 2014-01-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9034882B2 (en) 2012-03-05 2015-05-19 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9006235B2 (en) 2012-03-06 2015-04-14 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
RU2014115227A (ru) 2012-04-20 2015-10-27 Джилид Сайэнс, Инк. Производные бензотиазол-6-ил уксусной кислоты и их примение для лечения вич-инфекции
CA2871794A1 (en) * 2012-05-03 2013-11-07 Cipla Limited Antiretroviral composition
ES2647437T3 (es) * 2012-07-12 2017-12-21 Viiv Healthcare Uk Limited Compuestos y procedimientos para tratar el VIH
US8906929B2 (en) 2012-08-16 2014-12-09 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US20140094609A1 (en) * 2012-10-03 2014-04-03 Gilead Sciences, Inc. Process for the preparation of an hiv integrase inhibitor
US20140094485A1 (en) 2012-10-03 2014-04-03 Gilead Sciences, Inc. Solid state forms of hiv inhibitor
EP2716632A1 (en) 2012-10-05 2014-04-09 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2716639A1 (en) 2012-10-05 2014-04-09 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
EP2719685A1 (en) 2012-10-11 2014-04-16 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
LT3608325T (lt) 2012-12-21 2022-09-12 Gilead Sciences, Inc. Policikliniai karbamoilpiridono junginiai ir jų farmacinis naudojimas
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
PT2943487T (pt) 2013-01-09 2016-12-15 Gilead Sciences Inc Heteroarilos de 5 membros e sua utilização como agentes antivirais
NZ727792A (en) 2013-01-09 2018-04-27 Gilead Sciences Inc Therapeutic compounds
TW201441197A (zh) 2013-01-31 2014-11-01 Shionogi & Co Ｈｉｖ複製抑制劑
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
EP2970273B1 (en) 2013-03-13 2017-03-01 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
JP2016512511A (ja) 2013-03-13 2016-04-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヒト免疫不全ウイルス複製の阻害剤
JP2016516692A (ja) 2013-03-13 2016-06-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヒト免疫不全ウイルス複製の阻害剤
CN105189503B (zh) 2013-03-14 2017-03-22 百时美施贵宝公司 人免疫缺陷病毒复制的抑制剂
EP2970297A1 (en) 2013-03-14 2016-01-20 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
EP3010586A1 (en) 2013-06-21 2016-04-27 Lupin Limited Substituted heterocyclic compounds as crac modulators
CA2914415A1 (en) 2013-06-24 2014-12-31 Lupin Limited Chromane and chromene derivatives and their use as crac modulators
EP2821082A1 (en) 2013-07-05 2015-01-07 Laboratoire Biodim Method of producing an inactivated lentivirus, especially HIV, vaccine, kit and method of use
EP2821104A1 (en) 2013-07-05 2015-01-07 Laboratoire Biodim Inhibitors of viral replication, their process of preparation and their therapeutical uses
NO2865735T3 (ru) 2013-07-12 2018-07-21
ES2859102T3 (es) 2013-07-12 2021-10-01 Gilead Sciences Inc Compuestos de carbamoilpiridona policíclica y su uso para el tratamiento de infecciones por VIH
CN103467374A (zh) * 2013-08-30 2013-12-25 江苏弘和药物研发有限公司 一种8-溴-4-羧基喹啉的合成方法
EP3105236B1 (en) 2014-02-12 2017-10-18 ViiV Healthcare UK (No.5) Limited Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication
US9932353B2 (en) 2014-02-18 2018-04-03 Viiv Healthcare Uk (No. 5) Limited Imidazopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
US9409922B2 (en) 2014-02-18 2016-08-09 Bristol-Myers Squibb Company Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
US9834566B2 (en) 2014-02-18 2017-12-05 VIIV Healthcare UK (No.5) Limited Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
WO2015126765A1 (en) 2014-02-19 2015-08-27 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US9273067B2 (en) 2014-02-19 2016-03-01 Bristol-Myers Squibb Company Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication
US9193720B2 (en) 2014-02-20 2015-11-24 Bristol-Myers Squibb Company Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
PT3116880T (pt) 2014-02-20 2018-05-10 Viiv Healthcare Uk No 5 Ltd Macrociclos de ácido piridin-3-il acético como inibidores da replicação do vírus da imunodeficiência humana
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
US9975906B2 (en) 2014-05-16 2018-05-22 Shionogi & Co., Ltd. Tricyclic heterocycle derivatives having HIV replication inhibitory effect
WO2015179448A1 (en) * 2014-05-21 2015-11-26 Gilead Sciences, Inc. Therapeutic compounds
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (ru) 2014-06-20 2018-06-23
TWI733652B (zh) 2014-07-11 2021-07-21 美商基利科學股份有限公司 用於治療ＨＩＶ之ｔｏｌｌ樣受體調節劑
EP3172200B1 (en) 2014-07-22 2018-10-17 VIIV Healthcare UK Limited Isoindolinone derivatives useful as antiviral agents
WO2016036759A1 (en) 2014-09-04 2016-03-10 Gilead Sciences, Inc. Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir
EA201790369A1 (ru) 2014-09-16 2017-10-31 Джилид Сайэнс, Инк. Твердые формы модулятора толл-подобного рецептора
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
MX2017008518A (es) 2014-12-24 2017-10-25 Gilead Sciences Inc Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
AU2015371255B2 (en) 2014-12-24 2018-09-27 Gilead Sciences, Inc. Fused pyrimidine compounds for the treatment of HIV
TWI699355B (zh) 2014-12-24 2020-07-21 美商基利科學股份有限公司 喹唑啉化合物
SI3321265T1 (sl) 2015-03-04 2020-07-31 Gilead Sciences, Inc. Spojine 4,6-diamino-pirido(3,2-d)pirimidina in njihova uporaba kot modulatorji toličnih receptorjev
TR201905009T4 (tr) 2015-04-02 2019-05-21 Gilead Sciences Inc Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları.
EP3305789A4 (en) 2015-05-29 2018-11-21 Shionogi & Co., Ltd. Nitrogen-containing tricyclic derivative having hiv replication inhibitory activity
JP2018520162A (ja) 2015-07-06 2018-07-26 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
CN107835808A (zh) 2015-07-08 2018-03-23 Viiv保健英国第五有限公司 作为人类免疫缺陷性病毒复制的抑制剂的吡啶‑3‑基乙酸衍生物
JP2018519349A (ja) 2015-07-09 2018-07-19 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
JP2018519354A (ja) 2015-07-09 2018-07-19 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
US10709697B2 (en) 2015-07-16 2020-07-14 Emory University Bis-amines, compositions, and uses related to CXCR4 inhibition
US20190010139A1 (en) 2015-08-07 2019-01-10 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
AU2016305338A1 (en) 2015-08-10 2018-03-01 VIIV Healthcare UK (No.5) Limited Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
TWI657086B (zh) 2015-08-11 2019-04-21 英商Viiv醫療保健英國(No.5)有限公司 做為人類免疫缺陷病毒複製抑制劑之５－（ｎ－苯甲基四氫異喹啉－６－基）吡啶－３－基乙酸衍生物
EP3334722A1 (en) 2015-08-12 2018-06-20 VIIV Healthcare UK (No.5) Limited 5-(n-fused tricyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3- yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
TW201718537A (zh) 2015-08-12 2017-06-01 Ｖｉｉｖ醫療保健英國（Ｎｏ．５）有限公司 做為人類免疫缺陷病毒複製抑制劑之吡啶－３－基乙酸衍生物
EP3334723B1 (en) 2015-08-12 2019-09-18 VIIV Healthcare UK (No.5) Limited 5-(n-[6,5]-fused bicyclic aryl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
CN108368093A (zh) 2015-08-20 2018-08-03 Viiv保健英国第五有限公司 作为人免疫缺陷病毒复制的抑制剂的吡啶-3-基乙酸衍生物
MA42684A (fr) 2015-08-26 2018-07-04 Gilead Sciences Inc Modulateurs deutérés du récepteur toll
WO2017048727A1 (en) 2015-09-15 2017-03-23 Gilead Sciences, Inc. Modulators of toll-like recptors for the treatment of hiv
ES2797900T3 (es) 2015-09-30 2020-12-04 Gilead Sciences Inc Compuestos y combinaciones para el tratamiento del VIH
PE20181451A1 (es) 2015-12-15 2018-09-12 Gilead Sciences Inc Anticuerpos neutralizadores del virus de inmunodeficiencia humana
JP2019515000A (ja) 2016-05-11 2019-06-06 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
EP3455215A1 (en) 2016-05-11 2019-03-20 ViiV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
JP2019515939A (ja) 2016-05-11 2019-06-13 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
JP6998937B2 (ja) 2016-08-12 2022-01-18 バイエル・クロップサイエンス・アクチェンゲゼルシャフト ２－（２－ジアゾニウム－６－置換フェニル）エタノール塩を環化させることによる４－置換２，３－ジヒドロ－１－ベンゾフラン誘導体の製造方法
CR20190084A (es) 2016-08-19 2019-05-02 Gilead Sciences Inc Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéutico de una infección por el virus del vih
WO2018042331A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
WO2018042332A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
WO2018045150A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
PT3507276T (pt) 2016-09-02 2022-01-11 Gilead Sciences Inc Compostos moduladores do recetor de tipo toll
WO2018051250A1 (en) 2016-09-14 2018-03-22 Viiv Healthcare Company Combination comprising tenofovir alafenamide, bictegravir and 3tc
EP3519409A1 (en) 2016-09-28 2019-08-07 Gilead Sciences, Inc. Benzothiazol-6-yl acetic acid derivatives and their use for treating hiv infection
EP3532478B1 (en) 2016-10-27 2021-05-26 Gilead Sciences, Inc. Crystalline form of darunavir free base
WO2018127801A1 (en) 2017-01-03 2018-07-12 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
JP2020503348A (ja) 2017-01-03 2020-01-30 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体
WO2018138050A1 (de) 2017-01-26 2018-08-02 Bayer Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
TW202402300A (zh) 2017-01-31 2024-01-16 美商基利科學股份有限公司 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
ES2938335T3 (es) * 2017-03-24 2023-04-10 St Pharm Co Ltd Nuevo derivado de pirrolopiridina, método para producir el mismo y uso del mismo
TWI728250B (zh) 2017-06-21 2021-05-21 美商基利科學股份有限公司 靶向hiv gp120及cd3之多特異性抗體
US10851125B2 (en) 2017-08-01 2020-12-01 Gilead Sciences, Inc. Crystalline forms of ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl(-L-alaninate
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
TWI687415B (zh) 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
JP6934562B2 (ja) 2017-08-22 2021-09-15 ギリアード サイエンシーズ， インコーポレイテッド 治療用複素環式化合物
JOP20180092A1 (ar) 2017-10-13 2019-04-13 Gilead Sciences Inc مثبطات hiv بروتياز
US20190151307A1 (en) 2017-10-24 2019-05-23 Gilead Sciences, Inc. Methods of treating patients co-infected with a virus and tuberculosis
KR102492187B1 (ko) 2017-12-20 2023-01-27 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 3'3' 사이클릭 다이뉴클레오티드
EP3728282B1 (en) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
AU2019209594B2 (en) 2018-01-19 2021-09-23 Gilead Sciences, Inc. Metabolites of bictegravir
PL3752495T3 (pl) 2018-02-15 2024-01-15 Gilead Sciences, Inc. Pochodne pirydynowe i ich zastosowanie do leczenia infekcji hiv
PL3752496T3 (pl) 2018-02-16 2023-11-27 Gilead Sciences, Inc. Sposoby i związki pośrednie do wytwarzania związku terapeutycznego przydatnego w leczeniu infekcji wirusowej retroviridae
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
EP3774832A1 (en) 2018-04-06 2021-02-17 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotides
TW202014193A (zh) 2018-05-03 2020-04-16 捷克科學院有機化學與生物化學研究所 包含碳環核苷酸之2’3’－環二核苷酸
WO2019244066A2 (en) 2018-06-19 2019-12-26 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
WO2020003093A1 (en) 2018-06-25 2020-01-02 VIIV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
EP4257600A3 (en) 2018-07-03 2024-01-10 Gilead Sciences, Inc. Antibodies that target hiv gp120 and methods of use
US11098027B2 (en) 2018-07-06 2021-08-24 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
KR102629921B1 (ko) 2018-07-06 2024-01-31 길리애드 사이언시즈, 인코포레이티드 치료 헤테로시클릭 화합물
KR20210033492A (ko) 2018-07-16 2021-03-26 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료를 위한 캡시드 억제제
TWI766172B (zh) 2018-07-30 2022-06-01 美商基利科學股份有限公司 抗hiv化合物
KR20210060573A (ko) 2018-09-19 2021-05-26 길리애드 사이언시즈, 인코포레이티드 Hiv 예방용 인테그라제 억제제
WO2020072656A1 (en) 2018-10-03 2020-04-09 Gilead Sciences, Inc. Imidozopyrimidine derivatives
BR112021008255A2 (pt) 2018-10-31 2021-08-03 Gilead Sciences, Inc. compostos de 6-azabenzimidazol substituídos como inibidores de hpk1
KR20210084579A (ko) 2018-10-31 2021-07-07 길리애드 사이언시즈, 인코포레이티드 Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
WO2020176505A1 (en) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Protein kinase c agonists
WO2020176510A1 (en) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Protein kinase c agonists
CA3129011C (en) 2019-03-07 2023-12-19 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
KR20210137517A (ko) 2019-03-07 2021-11-17 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. 2'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
CA3128961A1 (en) 2019-03-22 2020-10-01 Hang CHU Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202104210A (zh) 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv蛋白酶抑制劑
WO2020214647A1 (en) 2019-04-17 2020-10-22 Gilead Sciences, Inc. Solid forms of an hiv protease inhibitor
TW202231277A (zh) 2019-05-21 2022-08-16 美商基利科學股份有限公司 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
RU2717101C1 (ru) 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
CA3140708A1 (en) 2019-06-18 2020-12-24 Helen Horton Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
JP7295283B2 (ja) 2019-06-25 2023-06-20 ギリアード サイエンシーズ， インコーポレイテッド Ｆｌｔ３ｌ－ｆｃ融合タンパク質及び使用方法
CA3145791A1 (en) 2019-07-16 2021-01-21 Gilead Sciences, Inc. Hiv vaccines and methods of making and using
US20220257619A1 (en) 2019-07-18 2022-08-18 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
EP4017476A1 (en) 2019-08-19 2022-06-29 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
EP4065116A1 (en) 2019-11-26 2022-10-05 Gilead Sciences, Inc. Capsid inhibitors for the prevention of hiv
EP4081305A1 (en) 2019-12-24 2022-11-02 Carna Biosciences, Inc. Diacylglycerol kinase modulating compounds
BR112022015771A2 (pt) 2020-02-24 2022-10-11 Gilead Sciences Inc Compostos tetracíclicos para tratar a infecção por hiv
CN115605493A (zh) 2020-03-20 2023-01-13 吉利德科学公司（Us） 4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法
WO2021236944A1 (en) 2020-05-21 2021-11-25 Gilead Sciences, Inc. Pharmaceutical compositions comprising bictegravir
TW202208362A (zh) 2020-06-25 2022-03-01 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
US20220119426A1 (en) 2020-08-07 2022-04-21 Gilead Sciences, Inc. Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
KR20230079137A (ko) 2020-09-30 2023-06-05 길리애드 사이언시즈, 인코포레이티드 가교된 트리사이클릭 카르바모일피리돈 화합물 및 이의 용도
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
JP2023549188A (ja) 2020-11-11 2023-11-22 ギリアード サイエンシーズ， インコーポレイテッド ｇｐ１２０ ＣＤ４結合部位指向性抗体による治療に感受性のＨＩＶ患者を特定する方法
US11613546B2 (en) 2021-01-19 2023-03-28 Gilead Sciences, Inc. Substituted pyridotriazine compounds and uses thereof
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
CN117396478A (zh) 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
CA3220923A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023102529A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
WO2023102239A1 (en) 2021-12-03 2023-06-08 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
TW202342447A (zh) 2021-12-03 2023-11-01 美商基利科學股份有限公司 用於ｈｉｖ病毒感染之治療性化合物
TW202400172A (zh) 2022-04-06 2024-01-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
US20240034724A1 (en) 2022-07-01 2024-02-01 Gilead Sciences, Inc. Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
WO2024015741A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
WO2024044477A1 (en) 2022-08-26 2024-02-29 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6463518A (en) 1987-09-02 1989-03-09 Otsuka Pharma Co Ltd Antiarrhythmic agent
AU4074789A (en) 1988-03-01 1989-09-22 Upjohn Company, The Coumarins to inhibit reverse transcriptase in humans
JPH03227923A (ja) 1990-01-30 1991-10-08 Sawai Seiyaku Kk ひと免疫不全ウイルス疾患処置剤
GB9005518D0 (en) 1990-03-12 1990-05-09 Wellcome Found Heterocyclic compounds
AU2436792A (en) * 1991-08-16 1993-03-16 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
DE4208304A1 (de) 1992-03-16 1993-09-23 Merck Patent Gmbh 2-oxochinolinderivate
NO179904C (no) * 1992-09-04 1997-01-08 Takeda Chemical Industries Ltd Kondenserte heterocykliske forbindelser og deres anvendelse
IL108459A0 (en) * 1993-02-05 1994-04-12 Opjohn Company 4-Hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl [B] pyran-2-ones useful for treating infections due to hiv and other retroviruses
DE19528418A1 (de) * 1995-08-02 1997-02-06 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
US6069151A (en) * 1996-11-06 2000-05-30 Darwin Discovery, Ltd. Quinolines and their therapeutic use
EP0994106B1 (en) 1996-12-26 2004-03-17 Shionogi & Co., Ltd. Process for the preparation of carbamoylated imidazole derivatives
FR2761687B1 (fr) * 1997-04-08 2000-09-15 Centre Nat Rech Scient Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques
FR2772761B1 (fr) 1997-12-23 2000-05-26 Lipha Nouveaux derives de n-phenylamide et n-pyridylamide, leur procede de preparation et compositions pharmaceutiques les contenant
US6307087B1 (en) 1998-07-10 2001-10-23 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
US6395916B1 (en) 1998-07-10 2002-05-28 Massachusetts Institute Of Technology Ligands for metals and improved metal-catalyzed processes based thereon
ID28959A (id) 1998-12-04 2001-07-19 Bristol Myers Squibb Co Turunan-turunan 3-tersubstitusi-4-arilkinolin-2-on sebagai modulator saluran kalium
WO2001057021A2 (en) 2000-02-01 2001-08-09 Cor Therapeutics, Inc. 2-[1H]-QUINOLONE AND 2-[1H]-QUINOXALONE INHIBITORS OF FACTOR Xa
FR2819507B1 (fr) * 2001-01-17 2007-09-28 Inst Rech Developpement Ird Quinoleines substituees pour le traitement de co-infections a protozoaires et a retrovirus
CA2446324A1 (en) 2001-05-21 2002-11-28 F. Hoffmann-La Roche Ag Quinoline derivatives as ligands for the neuropeptide y receptor
PL369960A1 (en) 2001-10-11 2005-05-02 Alcon, Inc. Methods for treating dry eye by a combination of an antiinflammatory steroid and a muc-1 secretagogue
DE10155076A1 (de) 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
FR2839646B1 (fr) * 2002-05-17 2008-04-11 Bioalliance Pharma Utilisation de derives de quinoleine a effet anti-integrase et ses applications
WO2004024693A1 (ja) * 2002-08-13 2004-03-25 Shionogi & Co., Ltd. Ｈｉｖインテグラーゼ阻害活性を有するヘテロ環化合物
MY136173A (en) 2002-11-20 2008-08-29 Japan Tobacco Inc 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
AR047329A1 (es) 2003-12-12 2006-01-18 Wyeth Corp Derivados de quinolinas para el tratamiento de enfermedades cardiovasculares. composiciones farmaceuticas
US20060094755A1 (en) * 2004-10-28 2006-05-04 Bioflexis, Llc Novel quinoline-based metal chelators as antiviral agents
EP1866313A1 (en) 2005-03-31 2007-12-19 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Hiv integrase inhibitors
EP1874117B8 (en) 2005-04-28 2014-03-12 VIIV Healthcare Company Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
JP2008542352A (ja) 2005-06-01 2008-11-27 ビオアリアンス ファルマ キノリン化合物及び他のｈｉｖ感染治療薬を含む相乗作用のコンビネーション
AU2006299042B8 (en) 2005-10-04 2011-09-15 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa HIV integrase inhibitors
KR20080064182A (ko) 2005-10-27 2008-07-08 시오노기세야쿠 가부시키가이샤 Ｈｉｖ 인테그라아제 억제활성을 가지는 다환성카르바모일피리돈 유도체
US7939545B2 (en) * 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
EP2220076B1 (en) 2007-11-15 2012-01-18 Boehringer Ingelheim International GmbH Inhibitors of human immunodeficiency virus replication
UA100250C2 (ru) 2007-11-16 2012-12-10 Гілеад Сайнсіз, Інк. Ингибиторы репликации вируса иммунодефицита человека
EP2694160A1 (en) 2011-04-04 2014-02-12 Gilead Sciences, Inc. Solid state forms of hiv inhibitor
JP2014511859A (ja) 2011-04-04 2014-05-19 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖインテグラーゼ阻害剤の調製のためのプロセス

Also Published As

Publication number Publication date
JP5285709B2 (ja) 2013-09-11
CN101918365B (zh) 2013-10-09
BRPI0820307A2 (pt) 2019-09-24
UA100250C2 (ru) 2012-12-10
PE20130009A1 (es) 2013-02-05
SG185995A1 (en) 2012-12-28
EA019259B1 (ru) 2014-02-28
AU2008323558A1 (en) 2009-05-22
MA31906B1 (fr) 2010-12-01
CL2008003406A1 (es) 2010-01-11
EP2220046A1 (en) 2010-08-25
US20140296228A1 (en) 2014-10-02
AU2008323558B2 (en) 2013-10-17
EA201000777A1 (ru) 2010-12-30
JP2011503116A (ja) 2011-01-27
US20100311735A1 (en) 2010-12-09
EP2757096A1 (en) 2014-07-23
IL205581A (en) 2014-06-30
HK1199731A1 (en) 2015-07-17
AU2008323558C1 (en) 2014-05-01
IL205581A0 (en) 2010-11-30
WO2009062285A1 (en) 2009-05-22
US8354429B2 (en) 2013-01-15
NZ585226A (en) 2012-08-31
EP2220046A4 (en) 2011-01-05
PE20130008A1 (es) 2013-02-05
TN2010000212A1 (en) 2011-11-11
MX2010005334A (es) 2010-05-27
HK1147096A1 (en) 2011-07-29
ZA201003283B (en) 2011-03-30
AR069335A1 (es) 2010-01-13
US8710230B2 (en) 2014-04-29
EP2757096A9 (en) 2014-11-26
UY31472A1 (es) 2009-07-17
TW200932227A (en) 2009-08-01
CN101918365A (zh) 2010-12-15
JP2013241410A (ja) 2013-12-05
CO6280400A2 (es) 2011-05-20
PE20091000A1 (es) 2009-08-14
EP2220046B1 (en) 2014-06-18
ECSP10010206A (es) 2010-06-29
KR20100097156A (ko) 2010-09-02
US20130197231A1 (en) 2013-08-01
CA2707418C (en) 2013-11-19
TWI437992B (zh) 2014-05-21
CA2707418A1 (en) 2009-05-22

Similar Documents

Publication Publication Date Title
EA201000777A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
EA201101620A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
CY1120457T1 (el) Αντι-ιικη θεραπεια
CY1118454T1 (el) Πρωτοτυποι αναστολεις πυρρολιου της αναγωγασης s-νιτροζογλουταθειονης ως θεραπευτικοι παραγοντες
CY1114981T1 (el) Προφαρμακα ντολουτεγκραβιρης
ATE541841T1 (de) Inhibitoren der replikation des human immunodeficiency virus
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
EA201071315A1 (ru) Ингибиторы протеазы вируса гепатита с
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
DK2004641T3 (da) HIV-inhiberende 5-(hydroxymethylen og aminomethylen) substituerede pyrimidiner
EA201170227A1 (ru) Имидазолкарбоксамиды
WO2008127364A3 (en) Antiviral compounds and use thereof
EA201000948A1 (ru) Ингибиторы вирусной полимеразы
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
EA201101397A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
CY1115919T1 (el) Ενωσεις ενεργοποιησης τελομερασης και μεθοδοι χρησης αυτων
EA200870515A1 (ru) Моноциклические гетероарильные соединения
WO2011150190A3 (en) Hcv inhibitor compounds and methods of use thereof
EA201290642A1 (ru) Соединения и способы
WO2011160024A3 (en) Compounds useful as antiviral agents, compositions, and methods of use
EA200901080A1 (ru) Новые нуклеозидные аналоги для лечения вирусных инфекций
CY1114488T1 (el) Διεργασιες και ενδιαμεσα για την παρασκευη ενος μακροκυκλικου αναστολεα πρωτεασης του hcv
EA201070009A1 (ru) Производные 7-алкинил-1,8-нафтиридонов, их получение и их применение в терапии
CR11423A (es) NUEVOS INHIBIDORES DE sEH Y SU USO
EA201270256A1 (ru) Производные т1-замещенного 5-фтор-2-оксопиримидинон-1 (2h) -карбоксамида